About BYSI

BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring is advancing its lead asset, Plinabulin, into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.
Primary Exchange: NASDAQ
SIC Medicinal Chemicals & Botanical Products
NAICS Medicinal and Botanical Manufacturing

BYSI is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ONEQ Fidelity Nasdaq Composite Index Tracking Stock 1.7 B 1.7E+09 1,015 1015 0.01% 5.36265E-05 93 K 93309

Wait, Before You Leave...